CN101141949B - 用于治疗帕金森病的药物组合物 - Google Patents

用于治疗帕金森病的药物组合物 Download PDF

Info

Publication number
CN101141949B
CN101141949B CN2006800088139A CN200680008813A CN101141949B CN 101141949 B CN101141949 B CN 101141949B CN 2006800088139 A CN2006800088139 A CN 2006800088139A CN 200680008813 A CN200680008813 A CN 200680008813A CN 101141949 B CN101141949 B CN 101141949B
Authority
CN
China
Prior art keywords
composition
particles
weight
present
carrier particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800088139A
Other languages
English (en)
Chinese (zh)
Other versions
CN101141949A (zh
Inventor
安德斯·彼得松
托马斯·伦德奎维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexo AB
Original Assignee
Orexo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo AB filed Critical Orexo AB
Publication of CN101141949A publication Critical patent/CN101141949A/zh
Application granted granted Critical
Publication of CN101141949B publication Critical patent/CN101141949B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800088139A 2005-03-28 2006-03-28 用于治疗帕金森病的药物组合物 Expired - Fee Related CN101141949B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66537605P 2005-03-28 2005-03-28
US60/665,376 2005-03-28
PCT/GB2006/001132 WO2006103417A1 (en) 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
CN101141949A CN101141949A (zh) 2008-03-12
CN101141949B true CN101141949B (zh) 2010-12-08

Family

ID=34956744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800088139A Expired - Fee Related CN101141949B (zh) 2005-03-28 2006-03-28 用于治疗帕金森病的药物组合物

Country Status (12)

Country Link
US (1) US20080193526A1 (https=)
EP (1) EP1863455A1 (https=)
JP (1) JP2008534563A (https=)
KR (1) KR20070114734A (https=)
CN (1) CN101141949B (https=)
CA (1) CA2599384A1 (https=)
IL (1) IL185300A0 (https=)
MX (1) MX2007011976A (https=)
NO (1) NO20074199L (https=)
NZ (1) NZ560826A (https=)
RU (1) RU2440100C2 (https=)
WO (1) WO2006103417A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US8377474B2 (en) * 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
KR101850479B1 (ko) 2015-07-22 2018-05-30 (주)듀켐바이오 [18F]플루오로-도파의 중성 pH 안정화 방법
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
WO2004067004A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414167B1 (https=) * 1970-12-28 1979-06-05
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
HU209564B (en) * 1991-01-30 1994-07-28 Egyt Gyogyszervegyeszeti Gyar Process for producing rapide tablets containing levodopa and carbidopa
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
WO2004067004A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JP昭54-14167B2 1979.06.05
王燕.帕金森病的药物治疗进展.湖北医药导报10 3.1991,10(3),9-11.
王燕.帕金森病的药物治疗进展.湖北医药导报10 3.1991,10(3),9-11. *

Also Published As

Publication number Publication date
US20080193526A1 (en) 2008-08-14
MX2007011976A (es) 2007-12-07
KR20070114734A (ko) 2007-12-04
CA2599384A1 (en) 2006-10-05
JP2008534563A (ja) 2008-08-28
CN101141949A (zh) 2008-03-12
RU2440100C2 (ru) 2012-01-20
RU2007139826A (ru) 2009-05-10
IL185300A0 (en) 2008-02-09
NO20074199L (no) 2007-11-21
NZ560826A (en) 2009-06-26
EP1863455A1 (en) 2007-12-12
WO2006103417A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CN101151021A (zh) 用于疼痛治疗的新药物组合物
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
US20090232898A1 (en) Pharmaceutical Compositions Useful in the Treatment of Migraine
HUP0103621A2 (hu) Fentanilkészítmény akut fájdalom kezelésére
CN101141949B (zh) 用于治疗帕金森病的药物组合物
US20180214437A1 (en) New alfentanil composition for the treatment of acute pain
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
AU2006228296B2 (en) New pharmaceutical compositions useful in the treatment of Parkinson's disease
WO2013164617A1 (en) New sufentanil composition for the treatment of acute pain
HK1233172A1 (en) New alfentanil composition for the treatment of acute pain
HK1233172B (en) New alfentanil composition for the treatment of acute pain
HK1203399B (en) New alfentanil composition for the treatment of acute pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101208

Termination date: 20120328